Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis

Introduction Cervical cancer is the fourth most frequent cancer in women worldwide. Addition of the VEGF antibody bevacizumab in combination with platinum-containing chemotherapy achieved an improvement in overall survival in advanced cervical cancer. To date there are no data on neoadjuvant use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Junker, Philip, Puppe, Julian, Thangarajah, Fabinshy, Domröse, Christian, Cepic, Angela, Morgenstern, Bernd, Ratiu, Dominik, Hellmich, Martin, Mallmann, Peter, Wirtz, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109715/
https://www.ncbi.nlm.nih.gov/pubmed/30158716
http://dx.doi.org/10.1055/a-0641-5588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109715/
https://www.ncbi.nlm.nih.gov/pubmed/30158716
http://dx.doi.org/10.1055/a-0641-5588

Ejemplares similares